Drug Profile
Research programme: GPCR modulators - Nxera Pharma
Alternative Names: allosteric modulators of metabotropic glutamate receptor (5mGluR5) - Nxera Pharma; calcitonin gene-related peptide (CGRP) modulators - Nxera Pharma; CNS disorder therapeutics - Nxera Pharma; H4 receptor antagonist - Nxera Pharma; M1/M4 agonist - Nxera Pharma; mGlus NAM - Nxera Pharma; muscarinic M1 agonists - Nxera Pharma; Orexin OX1 receptor antagonist - Nxera Pharma; Orexin OX1/OX2 dual receptor agonists; Orexin OX2 agonists - Nxera Pharma; OX-1 antagonist - Nxera PharmaLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Heptares Therapeutics
- Developer AbbVie; Medical Research Council; Nxera Pharma; Shire; Takeda; Tempero Bio
- Class Antimigraines; Anxiolytics; Drug withdrawal therapies; Neuroprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2A receptor antagonists; Calcitonin gene-related peptide antagonists; G protein-coupled receptor modulators; Histamine H4 receptor antagonists; Metabotropic glutamate receptor 5 antagonists; Metabotropic glutamate receptor 5 modulators; Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
- Research Anxiety disorders; Substance-related disorders
- No development reported Atopic dermatitis; Autistic disorder; Cocaine-related disorders; Cognition disorders; Depressive disorders; Migraine; Obsessive-compulsive disorders; Parkinson's disease; Psychotic disorders; Sleep disorders; Unspecified
Most Recent Events
- 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
- 28 Apr 2023 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom
- 01 Dec 2021 Preclinical trials in CNS disorders in United Kingdom (unspecified route) (Sosei Heptares pipeline, December 2021)